title: Effect of Buspirone, Fluoxetine and 8-OH-DPAT on Striatal Expression of Bax, Caspase-3 and Bcl-2 Proteins in 6-Hydroxydopamine-Induced Hemi-Parkinsonian Rats.
abstract: OBJECTIVE
  The exact pathogenesis of sporadic parkinson's disease (PD) is still unclear. Numerous evidences suggest involvement of apoptosis in the death of dopaminergic neurons. In this study we investigated the effect of sub-chronic administration of buspirone, fluoxetine and 8-hydroxy-2-[di-n-propylamino]tetralin (8-OH-DPAT) in 6-hydroxydopamine (6-OHDA)-lesioned rats and assayed striatal concentrations of apoptotic (Bax, Caspase3) and anti-apoptotic (Bcl-2) proteins.
  
  
  METHODS
  6-OHDA (8μg/2μl/rat) was injected unilaterally into the central region of the substantia nigra pars copmacta (SNc) of male Wistar rats and then, after 21 days lesioned rats were treated with intraperitonel (i.p) 1 mg/kg injections of buspirone, fluoxetine and 8-OH-DPAT for 10 consecutive days. Striatum of rats was removed at tenth day of drugs administration and were analyzed by western blotting method to measure Bax, caspase3 and Bcl-2 expression.
  
  
  RESULTS
  The results showed that the expression of Bax and caspase3 proteins was increased three weeks after 6-OHDA injection while they were decreased significantly in parkinsonian rats which were treated by buspirone, fluoxetine and 8-OH-DPAT. Bcl-2 was decreased and increased in parkinsonian rats and parkinsonian rats treated with buspirone, fluoxetine and 8-OH-DPAT, respectively.
  
  
  CONCLUSIONS
  Our study indicates that sub-chronic administration of serotonergic drugs such as buspirone, fluoxetine and 8-OH-DPAT restores striatal concentration of apoptotic and anti-apoptotic factors to the basal levels of normal non-lesioned rats. We suggest that these drugs can be used as a potential adjunctive therapy in PD through attenuating neuronal apoptotic process.
authors.affiliation: Department of Pharmacology, Faculty of Pharmacy, Urmia University of Medical Sciences, Urmia, Iran.
authors.forename: Hamdollah
authors.initials: H
authors.lastname: Sharifi
authors.affiliation: Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
authors.forename: Alireza
authors.initials: A
authors.lastname: Mohajjel Nayebi
authors.affiliation: Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
authors.forename: Safar
authors.initials: S
authors.lastname: Farajnia
authors.affiliation: Department of Pharmacology and Toxicology, Faculty of Pharmacy, Hamadan University of Medical Science, Hamadan, Iran.
authors.forename: Rasool
authors.initials: R
authors.lastname: Haddadi
keywords: 8-OH-DPAT; Apoptosis; Buspirone; Fluoxetine; Parkinson's Disease
references.citation: J Immunol. 2001 Jun 15;166(12):7345-52
references.pmid: 11390485
references.citation: Iran J Basic Med Sci. 2013 Dec;16(12):1270-5
references.pmid: 24570834
references.citation: Biochim Biophys Acta. 2003 Apr 7;1640(1):85-96
references.pmid: 12676358
references.citation: Prog Neurobiol. 2004 Jan;72(1):1-25
references.pmid: 15019174
references.citation: Adv Pharm Bull. 2012;2(2):149-55
references.pmid: 24312786
references.citation: CNS Drug Rev. 2005 Winter;11(4):379-402
references.pmid: 16614737
references.citation: Exp Neurol. 2007 Feb;203(2):302-8
references.pmid: 17069804
references.citation: Daru. 2011;19(5):338-43
references.pmid: 22615679
references.citation: Neurobiol Dis. 2002 Jun;10(1):28-32
references.pmid: 12079401
references.citation: Biochim Biophys Acta. 2007 Jun;1773(6):691-3
references.pmid: 17346815
references.citation: Brain Res Rev. 2007 Jun;54(2):233-50
references.pmid: 17408564
references.citation: Apoptosis. 2009 Apr;14(4):478-500
references.pmid: 19165601
references.citation: J Neurosci. 2001 Apr 1;21(7):2247-55
references.pmid: 11264300
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2012 Jan 10;36(1):92-100
references.pmid: 22019604
references.citation: Neuroreport. 2003 Jan 20;14(1):57-60
references.pmid: 12544831
references.citation: Adv Pharm Bull. 2013;3(1):203-6
references.pmid: 24312836
references.citation: Prog Neurobiol. 2010 Nov;92(3):316-29
references.pmid: 20541584
references.citation: Anesth Analg. 2010 Nov;111(5):1316-21
references.pmid: 20736434
references.citation: Pharm Biol. 2013 Feb;51(2):190-6
references.pmid: 23035972
references.citation: Nat Rev Mol Cell Biol. 2000 Nov;1(2):120-9
references.pmid: 11253364
references.citation: Pharmacol Rep. 2011;63(4):908-14
references.pmid: 22001978
references.citation: Adv Pharm Bull. 2012;2(1):127-31
references.pmid: 24312782
references.citation: J Neurochem. 2005 May;93(4):910-7
references.pmid: 15857394
references.citation: J Neurosci. 2003 Jun 15;23(12):5069-78
references.pmid: 12832530
references.citation: J Neurotrauma. 2001 Dec;18(12):1313-21
references.pmid: 11780862
references.citation: Neuroscience. 2001;107(3):405-13
references.pmid: 11718996
references.citation: J Neurocytol. 2004 Mar;33(2):213-23
references.pmid: 15322379
references.citation: J Neural Transm (Vienna). 2002 May;109(5-6):731-45
references.pmid: 12111464
references.citation: Nature. 2000 Oct 12;407(6805):802-9
references.pmid: 11048732
references.citation: Eur J Pharmacol. 1999 Apr 9;370(2):211-6
references.pmid: 10323272